子宫内膜异位症中PTEN与ARID1A体细胞缺失与疾病负担的纵向研究
前瞻性纵向研究纳入126例2013-2017年接受手术的子宫内膜异位症患者,随访5-9年,评估PTEN和ARID1A体细胞缺失与疾病负担及临床结局的关联。PTEN缺失与更严重解剖亚型、更高rASRM分期及更大手术难度相关,ARID1A缺失结果类似但样本量有限。
要点
- PTEN缺失见于68.3%患者,ARID1A缺失见于24.6%患者。
- PTEN缺失与更严重解剖亚型及更高rASRM分期显著相关。
- PTEN或ARID1A状态与基线及随访疼痛评分无差异。
核心结论
- 子宫内膜异位症上皮PTEN体细胞缺失与更大疾病负担和后续手术复杂性相关。
- 结果提示PTEN缺失及其他体细胞驱动突变可能对未来分子分型有潜在意义。
研究设计与样本
- 前瞻性纵向研究,纳入126例在三级中心接受子宫内膜异位症手术的参与者(2013-2017年),随访5-9年。
- 采用免疫组化方法评估PTEN和ARID1A缺失,由两名独立评估者判定。
- PTEN和ARID1A状态定义为缺失(至少一个样本缺失)或保留(所有样本无缺失)。
主要发现
- PTEN缺失68.3%(86例)高于ARID1A缺失24.6%(31例)。
- PTEN缺失与更严重解剖亚型显著相关(P < 0.001;仅SUP者46.4%,仅DE或仅OMA者72.7%,混合亚型者85.1%)。
- PTEN缺失与更高rASRM分期显著相关(P = 0.024;I期47.8%,II期73.7%,III期80.8%,IV期81.0%)。
- ARID1A缺失结果与PTEN类似,但样本量较小限制了检验效能。
- PTEN缺失还与少数族裔(P = 0.017)及更大手术难度(更常需输尿管松解术)(P = 0.02)相关;疼痛评分无差异;再手术不常见(13.5%),基于体细胞改变的再手术率模式未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未进行测序以确定导致表达缺失的PTEN和ARID1A体细胞突变类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there an association between the somatic loss of PTEN (phosphatase and tensin homolog) and ARID1A (AT-rich interaction domain 1A) and endometriosis disease severity and worse clinical outcomes? SUMMARY ANSWER: Somatic PTEN loss in endometriosis epithelium was associated with greater disease burden and subsequent surgical complexity. WHAT IS KNOWN ALREADY: Somatic cancer-driver mutations including those involving the PTEN and ARID1A genes exist in endometriosis without cancer; however, their clinical impact remains unclear. STUDY DESIGN, SIZE, DURATION: This prospective longitudinal study involved endometriosis tissue and clinical data from 126 participants who underwent surgery at a tertiary center for endometriosis (2013-2017), with a follow-up period of 5-9 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: PTEN and ARID1A loss was assessed using established immunohistochemistry (IHC) methods as proxies for somatic loss by two independent raters. PTEN and ARID1A status for each participant was defined as loss (loss in at least one sample for a participant) or retained (no loss in all samples for a participant). Primary analyses examined associations between PTEN and ARID1A loss and disease burden based on anatomic subtype (superficial peritoneal endometriosis (SUP), deep endometriosis (DE), ovarian endometrioma (OMA)) and rASRM stage (I-IV). Secondary analyses explored associations of PTEN and ARID1A loss with demographics, surgical difficulty, and pain scores (baseline and follow-up). Additionally, using previously published data on KRAS codon 12 mutations for this cohort, we investigated associations between variables in the primary and secondary analyses and acquiring two or more somatic events (PTEN loss, ARID1A loss, or KRAS mutation) in this cohort. The risk of reoperation over the 5-9 years was also examined. MAIN RESULTS AND THE ROLE OF CHANCE: PTEN loss (68.3%; 86 participants) exceeded ARID1A loss (24.6%; 31 participants). Inter-rater reliability was substantial for PTEN (k = 0.69; 95% CI: 0.62-0.77) and ARID1A (k = 0.64; 95% CI: 0.51-0.77). PTEN loss was significantly associated with more severe anatomic subtypes (P < 0.001; participants with SUP only = 46.4%; participants with DE only or OMA only = 72.7%; participants with mixed subtypes = 85.1%), and higher stages (P = 0.024; Stage I = 47.8%; Stage II = 73.7%; Stage III = 80.8%; Stage IV = 81.0%). Results were similar for ARID1A loss, albeit with smaller sample size limiting power. PTEN loss was further associated with non-White ethnicities (P = 0.017) and greater surgical difficulty (more frequent need for ureterolysis) (P = 0.02). There were no differences in pain scores (baseline or follow-up) based on PTEN or ARID1A status. Reoperation was uncommon (13.5% of the cohort), and patterns in reoperation rates based on the presence of somatic alterations did not reach statistical significance. LIMITATIONS, REASONS FOR CAUTION: Sequencing was not performed to determine the type of PTEN and ARID1A somatic mutations resulting in loss of expression. WIDER IMPLICATIONS OF THE FINDINGS: These results demonstrate a link between PTEN somatic loss and greater endometriosis disease burden. These findings underscore the potential relevance of PTEN loss and other somatic driver mutations in a future molecular classification of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Canadian Institutes of Health Research (CIHR) project grant (MOP-142273 and PJT-156084). P.J.Y. was supported by a Health Professional Investigator award from Michael Smith Health Research BC, Canada, and a Canada Research Chair (Tier 2) in Endometriosis and Pelvic Pain. M.S.A. was supported by a Michael Smith Health Research BC Scholar award, and CIHR project grants (369990, 462997, and 456767). The sponsors did not play any role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. C.A. declares receiving payment from Pfizer for a symposium; being on advisory boards for AbbVie and Pfizer; being President and past President of the Canadian Society for the Advancement of Gynecologic Excellence (CanSAGE), co-lead of EndoAct Canada, and a board member of IPPS. M.A.B. has received consulting fees from AbbVie and Pfizer and grants from Ferring outside the scope of this work. D.G.H. is the founder of Canxeia Health but has no current affiliation. M.K. has received consulting fees from Helix Biopharma outside the scope of this work. M.S.A. received reimbursement of travel and registration fees to attend and present at the 2023 and 2024 annual meetings for the Society for Reproductive Investigation (SRI). P.J.Y. declares receiving: payment for a lecture from the International Society for the Study of Women's Sexual Health (ISSWSH); honoraria from the CIHR; support to attend meetings from CanSAGE, ISSWSH, the International Pelvic Pain Society, the World Endometriosis Society (WES), the Society for the Study of Reproduction, and the Vulvodynia Summit; and discounted devices from Ohnut Wearable for a clinical trial. P.J.Y. is a data safety monitoring board member of a clinical trial funded by CIHR; and a strategic advisory board member for the Women's Health Research Institute. P.J.Y. served as a board of directors member for CanSAGE and ISSWSH; was a junior board of directors member for WES; is a current board of directors member for WES; and was a committee chair for the Society of Obstetricians and Gynaecologists of Canada. A subset of these results was presented by the first author at the 71st Society for Reproductive Investigation Annual Scientific Meeting on 15 March 2024. Other authors have nothing to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Tucker DR, Lee AF, Orr NL, et al. Somatic PTEN and ARID1A loss and endometriosis disease burden: a longitudinal study. Hum Reprod. 2025. PMID: 39701665. doi:10.1093/humrep/deae269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。